LGALS3 and cirrhosis of liver: Clinical trials of the galectin-3 inhibitors GB1211 and Belapectin for the treatment of liver cirrhosis are currently in phase II clinical trials (ClinicalTrials.gov Identifier: NCT05009680, NCT02462967).